Oncology

The therapy is administered via an intratumoral injection every 2 weeks for 8 consecutive doses.

Residency ranking often shifts from structured metrics to “fit” and vibes, risking bias toward familiarity; refocus decisions on evidence, values, and potential.

A review offering guidance to pharmacists on the importance of peer review as well as a tutorial on how to perform and respond to peer review.

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

Zongertinib offers durable activity in HER2-mutant NSCLC while highlighting pharmacists’ essential role in biomarker verification, dosing, medication review, adherence, and toxicity management.

ASCO 2026 spotlights PROTEUS shifts, new breast cancer data, lung cancer treatment advances, and daxonrasib gains hope in pancreatic cancer.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

FDA-cleared HPV self-collection kits like Teal Wand expand cervical cancer screening; pharmacists support follow-up, HPV education, and Gardasil.

Radiopharmaceuticals force oncology pharmacists to master safety, timing, waste, and costs—see how departments build radioactive therapy workflows.

The FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan introduces PSMA-targeted radioligand therapy to mHSPC.

World Lung Cancer Day presents an opportunity to recognize progress in lung cancer care while emphasizing the persistent need for earlier detection and equitable access to treatment.

Predictive scheduling can improve staffing, pharmacy preparation, infusion capacity, and the overall patient experience.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.

This roundup highlights 5 key solid tumor updates from July 2026, including new FDA approvals across bladder, breast, and lung cancers, a tissue-agnostic targeted therapy, and a blood-based colorectal cancer screening test.

The phase 2 AZTEC trial found that single- and multifraction SABR, followed by atezolizumab, had similar safety profiles and limited efficacy in advanced TNBC.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

Advance verification, multidisciplinary coordination, and AI-enabled forecasting can help infusion centers adjust schedules and treatment plans during chemotherapy shortages.

Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.

The FDA approved SimpleScreen CRC, a blood-based screening test for average-risk adults aged 45 and older, potentially expanding screening access.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

This week's episode covers a new AHA scientific statement on caffeine safety and cardiovascular benefit; pharmacist guidance for protecting patients with asthma, COPD, and allergies during wildfire smoke events; and regulatory updates in obstructive sleep apnea and ROS1-positive lung cancer.

Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.